Outcome of Board Meeting held on Tuesday, 20th May, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Hemo Organic Ltd approved the audited financial results for the quarter and year ended 31st March 2025. For Q4 FY25, revenue from operations jumped sharply to Rs. 241.43 lakhs (vs Rs. 2.24 lakhs in Q4 FY24), and the company reported a profit after tax of Rs. 37.34 lakhs versus a loss of Rs. 12.72 lakhs in the year-ago quarter. For the full year FY25, total income was Rs. 248.42 lakhs and profit after tax was Rs. 16.39 lakhs compared to a loss of Rs. 26.41 lakhs in FY24. However, the statutory auditor issued a qualified opinion because balance confirmations for trade receivables and payables were not provided. The board also appointed M/s. Jay Pandya & Associates as Secretarial Auditor and M/s. Umesh Khese & Co. as Internal Auditor for FY25. Note 6 flags that accumulated losses have wiped out paid-up capital and reserves, and current liabilities exceed current assets.
The sharp top-line growth and return to profitability look positive on the surface, but the qualified audit opinion, negative other equity (Rs. -361.74 lakhs), and current liabilities exceeding current assets are serious red flags about financial health and disclosure quality. Shareholders should treat the headline profit with caution until the auditor's qualification and balance-sheet weakness are resolved.